Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica WT Leung"'
Autor:
Zijian Zhou, Nabil A Elshafeey, David E Rauch, Beatriz E Adrada, Rosalind P Candelaria, Mary S Guirguis, Wei Yang, Medine Boge, Rania M Mohamed, Gary J Whitman, Deanna L Lane, Huong C Le-Petross, Jessica WT Leung, Lumarie Santiago, Marion E Scoggins, David A Spak, Miral M Patel, Frances Perez, Debu Tripathy, Vicente Valero, Clinton Yam, Stacy Moulder, Jason B White, Jong Bum Son, Mark D Pagel, Jingfei Ma
Publikováno v:
Cancer Research. 82:P1-08
Introduction: Neoadjuvant chemotherapy (NACT) is becoming standard of care for presurgical treatment of triple negative breast cancer (TNBC) patients. Achievement of pathological complete response (pCR) after NACT is associated with improved outcomes
Autor:
Henry M Kuerer, Benjamin D Smith, Savitri Krishnamurthy, Wei T Yang, Vicente Valero, Yu Shen, Heather Lin, Anthony Lucci, Judy C Boughey, Richard L White, Emilia J Diego, Gaiane M Rauch, Tanya W Moseley, Raquel FD van la Parra, Beatriz E Adrada, Jessica WT Leung, Susie X Sun, Mediget Teshome, Makesha V Miggins, Kelly K Hunt, Sarah M DeSnyder, Richard A Ehlers, Rosa F Hwang, Jessica S Colen, Elsa Arribas, Laila Samiian, Beth-Ann Lesnikoski, Mathew Piotrowski, Isabelle Bedrosian, Clayton Chong, Ana P Refinetti, Monica Huang, Rosalind P Candelaria, Catherine Loveland-Jones, Melissa P Mitchell, Simona F Shaitelman
Publikováno v:
The Lancet. Oncology. 23(12)
Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer yields a pathological complete response in approximately 60% of patients. A pathological complete response to NST predicts an excellent prognosis and
Autor:
Miral M Patel, Beatriz E Adrada, Benjamin Lopez, Rosalind P Candelaria, Jia Sun, Medine Boge, Rania M Mohamed, Nabil Elshafeey, Gary Whitman, Huong T Le-Petross, Lumarie Santiago, Marion E Scoggins, Deanna Lane, Tanya Moseley, Galit Zylberman, Jerica Saddler, Jessica WT Leung, Wei T Yang, Vincente Valero, S Cheenu Kappadath, Gaiane M Rauch
Publikováno v:
Cancer Research. 82:P3-02
BACKGROUND: Increasing use of neoadjuvant systemic therapy (NAT) for early and locally advanced breast cancer led to critical need for development of tools capable of early treatment response assessment after NAT. Tc-99m sestamibi Molecular breast Im
Autor:
Mary S Guirguis, Beatriz E Adrada, Rosalind P Candelaria, Jia Sun, Gary J Whitman, Wei T Yang, Medine Boge, Rania M Mohamed, Nabil A Elshafeey, Deanna L Lane, Huong Le-Petross, Jessica WT Leung, Lumarie Santiago, Marion E Scoggins, David A Spak, Miral Patel, Frances Perez, Peng Wei, Debu Tripathy, Jason White, Elizabeth Ravenberg, Lei Huo, Jennifer Litton, Banu Arun, Vincente Valero, Alastair Thompson, Stacy Moulder, Clinton Yam, Gaiane M Rauch
Publikováno v:
Cancer Research. 82:P3-03
Background: Triple negative breast cancer (TNBC) has a poor prognosis. In particular, TNBC patients who have significant residual disease at the time of surgery following completion of neoadjuvant systemic therapy (NST) have an especially poor progno